Canaccord raised the firm’s price target on GeneDx (WGS) to $160 from $155 and keeps a Buy rating on the shares. The firm said they remain bullish after another quarter of solid execution and continued profitable growth, driving increased long-term estimates. Canaccord noted GeneDx’s strategy to convert existing customers to WES/WGS and ramp new indications is driving solid growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target raised to $170 from $115 at Guggenheim
- Genedx Holdings Corp. Maintains Stable Risk Profile in 2025 Reports
- GeneDx Reports Strong Q3 2025 Financial Growth
- GeneDx’s Earnings Call Highlights Robust Growth and Optimism
- GeneDx Holdings: Strong Q3 Performance and Strategic Expansion in Pediatric Market Drive Optimistic Outlook